×
返回 Agenda
Session 5: Case Studies from Recent Approvals of RWD/RWE Submissions
Session Chair(s)
Yun Lu, PHD, MS
Deputy Division Director, DABRA, OBPV, CBER, FDA, United States
Session 5: Case Studies from Recent Approvals of RWD/RWE Submissions
Learning Objective : At the conclusion of this session, participants should be able to:- Explore FDA and pharmaceutical industry perspectives on the potential role of RWE in regulatory decision-making
- Identify relevant considerations for the use of RWD and RWE to support regulatory decision-making
- Apply lessons learned from recent use cases including submissions containing RWE to support safety and effectiveness
Speaker(s)
Kimberly Smith, MD, MS
Real-World Evidence Analytics Team, Office of Medical Policy, CDER, FDA, United States
CDER RWE Program: Update and Examples
Donna Rivera, PHARMD, MSC, FISPE
Executive Vice President-Clinical Evidence Modernization, Canal Row Advisors, United States
Oncology RWE Program: Overview and Regulatory Perspective on Effectiveness
Adrian Cassidy, PHD, MSC
Head Global Evidence Generation, Novartis, Switzerland
FDA Accelerated Aproval Based on Real-World Evidence